Search - tctmd.com

Displaying 21 - 40 of 92

Sort: Relevancy | Date

News Daily News

High TEE Injury Rate in Structural Heart Interventions Warrants Caution

Yael L. Maxwell

June 24, 2020

News Conference News TVT 2020

Newer TAVR Devices Reassure in Failed Surgical Valves

Shelley Wood

June 20, 2020

News Conference News ACC 2020

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

Michael O'Riordan

March 19, 2020

News Features

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Yael L. Maxwell

August 02, 2019

News Daily News

Machine Learning Helps Predict In-Hospital Mortality Post-TAVR, but Skepticism Abounds

Todd Neale

July 19, 2019

News Conference News TVT 2019

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Shelley Wood

June 14, 2019

News Daily News

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Michael O'Riordan

March 27, 2019

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Daily News

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Yael L. Maxwell

August 17, 2018

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Podcast

Episode 16: Healthcare Reform, Embolic Protection in TAVR, and More

August 10, 2017

Presentation TVT 2017

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Presenter: David J. Cohen, Jeffrey J. Popma, Robert O. Bonow

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Philippe Généreux

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: David J. Cohen, Jeffrey J. Popma, Nicolas M. Van Mieghem

June 16, 2017

Presentation TVT 2017

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

Presenter: David J. Cohen, Jeffrey J. Popma, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

Presenter: David J. Cohen, Jeffrey J. Popma, Martin B. Leon

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Advertisement

High TEE Injury Rate in Structural Heart Interventions Warrants Caution

Newer TAVR Devices Reassure in Failed Surgical Valves

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Machine Learning Helps Predict In-Hospital Mortality Post-TAVR, but Skepticism Abounds

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Episode 16: Healthcare Reform, Embolic Protection in TAVR, and More

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content